Skip to main content
Premium Trial:

Request an Annual Quote

Preliminary One-patient Data Suggest Benitec HCV Drug Safe, Well Tolerated


NEW YORK (GenomeWeb) – Benitec Biopharma said this week that laboratory data on the first patient dosed in its Phase I/IIa trial its expressed RNAi treatment for hepatitis C indicate that the drug is safe and well tolerated.

TT-034 is designed to express shRNAs targeting three regions of the HCV genome. The clinical study, which is set to enroll up to 14 HCV patients, began in June.

Benitec also said that a second patient has been identified for dosing in the study, just weeks after disclosing that two potential trial participants had failed to meet its inclusion criteria due to fluctuations in viral load and liver enzymes that were outside of acceptable ranges.

According to the firm, the newly identified patient is currently within the study protocol's clinical parameters and that they will receive TT-034 upon the successful completion of a 28-day screening process.

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.